Metadata Search Funding Data Link References Status API Help
Facet browsing currently unavailable
Page 4 of 151 results
Sort by: relevance publication year

Body composition as predictor of waiting list mortality in patients with end-stage liver cirrhosis

JOURNAL ARTICLE published September 2018 in Clinical Nutrition

Authors: D. Bot | A. Droop | C.J. Lucassen | M.E. van Veen | J.L.A. van Vugt | S. Feshtali | E. Leistra | B. van Hoek

Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1

JOURNAL ARTICLE published September 2018 in Clinical Lymphoma Myeloma and Leukemia

Authors: Frederick L. Locke | Armin Ghobadi | Caron A. Jacobson | Eric Jacobsen | David B. Miklos | Lazaros J. Lekakis | Ira Braunschweig | Olalekan O. Oluwole | Yi Lin | Tanya Siddiqi | Abhinav Deol | Patrick M. Reagan | Umar Farooq | Adrian Bot | Yizhou Jiang | John M. Rossi | Allen Xue | William Y. Go | Sattva S. Neelapu

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

JOURNAL ARTICLE published 20 May 2018 in Journal of Clinical Oncology

Authors: Frederick Lundry Locke | Armin Ghobadi | Lazaros J. Lekakis | David Bernard Miklos | Caron A. Jacobson | Eric D. Jacobsen | Ira Braunschweig | Olalekan O. Oluwole | Tanya Siddiqi | Yi Lin | Patrick Michael Reagan | Umar Farooq | Abhinav Deol | Adrian Bot | John M. Rossi | Yizhou Jiang | Allen Xue | William Y. Go | Sattva Swarup Neelapu

Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

JOURNAL ARTICLE published 20 May 2018 in Journal of Clinical Oncology

Authors: Frederick Lundry Locke | Armin Ghobadi | Caron A. Jacobson | Eric D. Jacobsen | David Bernard Miklos | Lazaros J. Lekakis | Ira Braunschweig | Olalekan O. Oluwole | Yi Lin | Tanya Siddiqi | Abhinav Deol | Patrick Michael Reagan | Umar Farooq | Adrian Bot | Yizhou Jiang | John M. Rossi | Allen Xue | William Y. Go | Sattva Swarup Neelapu

A phase I, open-label, dose-escalation and cohort expansion study evaluating the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma.

JOURNAL ARTICLE published 20 February 2018 in Journal of Clinical Oncology

Authors: Izak Faiena | Nazy Zomorodian | Begonya Comin-Anduix | Ankush Sachadeva | Adrian Bot | Fariouz Kabinnivar | Jonathan W. Said | Gardenia Cheung-Lau | Jia Pang | Mignonette Macabali | Paula Cabrera | Paula Kaplan-Lefko | Beata Berent-Maoz | Sandy Liu | Allan J. Pantuck | Arie S. Belldegrun | Karim Chamie | Alexandra Drakaki

Correction to: Lind, Simonsen, Bjønness Ribu, Svendsen, Svennevig, and de Bot, Lexical access in a bilingual speaker with dementia: Changes over time

JOURNAL ARTICLE published 3 July 2018 in Clinical Linguistics & Phonetics

Lexical access in a bilingual speaker with dementia: Changes over time

JOURNAL ARTICLE published 3 April 2018 in Clinical Linguistics & Phonetics

Research funded by The Research Council of Norway (223265)

Authors: Marianne Lind | Hanne Gram Simonsen | Ingeborg Sophie Bjønness Ribu | Bente Ailin Svendsen | Jan Svennevig | Kees de Bot

SUN-P060: Ascites Volume Assessed by Computer Tomography

JOURNAL ARTICLE published September 2017 in Clinical Nutrition

Authors: I. Krijger | A. Droop | D. Bot | J. Langius | S. Shahbazi Feshtali | B. Van Hoek

SUN-P067: Low Muscle Attenuation before Liver Transplantation, Length of Hospital and ICU Stay and Survival in Patients after Liver Transplantation

JOURNAL ARTICLE published September 2017 in Clinical Nutrition

Authors: D. Bot | A. Droop | M. Lelieveld | A. Donker | S. Shahbazi Feshtali | J. Langius | B.V. Hoek

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

JOURNAL ARTICLE published 1 June 2017 in Journal of Clinical Oncology

Authors: James N. Kochenderfer | Robert P.T. Somerville | Tangying Lu | Victoria Shi | Adrian Bot | John Rossi | Allen Xue | Stephanie L. Goff | James C. Yang | Richard M. Sherry | Christopher A. Klebanoff | Udai S. Kammula | Marika Sherman | Arianne Perez | Constance M. Yuan | Tatyana Feldman | Jonathan W. Friedberg | Mark J. Roschewski | Steven A. Feldman | Lori McIntyre | Mary Ann Toomey | Steven A. Rosenberg

Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel).

JOURNAL ARTICLE published 20 May 2017 in Journal of Clinical Oncology

Authors: Frederick Lundry Locke | John Rossi | Sattva Swarup Neelapu | Allen Xue | Marc Better | Xiao Zhang | Armin Ghobadi | Lazaros J. Lekakis | David Bernard Miklos | Caron Alyce Jacobson | Ira Braunschweig | Olalekan O. Oluwole | Tanya Siddiqi | Yi Lin | John Timmerman | Patrick Michael Reagan | Lynn Navale | William Y. Go | Jeffrey S. Wiezorek | Adrian Bot

Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).

JOURNAL ARTICLE published 20 May 2017 in Journal of Clinical Oncology

Authors: Frederick Lundry Locke | Sattva Swarup Neelapu | Nancy L. Bartlett | Lazaros J. Lekakis | David Bernard Miklos | Caron Alyce Jacobson | Ira Braunschweig | Olalekan O. Oluwole | Tanya Siddiqi | Yi Lin | John Timmerman | Patrick Michael Reagan | Adrian Bot | John Rossi | Lynn Navale | Yizhou Jiang | Jeff Aycock | Meg Elias | Jeffrey S. Wiezorek | William Y. Go

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

JOURNAL ARTICLE published 20 May 2017 in Journal of Clinical Oncology

Authors: Bijal D. Shah | William G. Wierda | Gary J. Schiller | Michael Russell Bishop | Januario E. Castro | Marianna Sabatino | Adrian Bot | Armen Mardiros | John Rossi | Yizhou Jiang | Lynn Navale | Shanna Stout | Jeff Aycock | Jeffrey S. Wiezorek | Rajul K. Jain

Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).

JOURNAL ARTICLE published 20 May 2017 in Journal of Clinical Oncology

Authors: Jerome Galon | John Rossi | Sarah Turcan | Corinne Danan | Frederick Lundry Locke | Sattva Swarup Neelapu | David Bernard Miklos | Nancy L. Bartlett | Caron Alyce Jacobson | Ira Braunschweig | Olalekan O. Oluwole | Tanya Siddiqi | Yi Lin | John Timmerman | Patrick Michael Reagan | Lazaros J. Lekakis | Sherryonne Unabia | William Y. Go | Jeffrey S. Wiezorek | Adrian Bot

Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL).

JOURNAL ARTICLE published 20 May 2017 in Journal of Clinical Oncology

Authors: Frederick Lundry Locke | Jason R. Westin | David Bernard Miklos | Alex Francisco Herrera | Caron Alyce Jacobson | Lillian Lee | John Rossi | Adrian Bot | Allen Xue | Lynn Navale | Jeff Aycock | Jeffrey S. Wiezorek | Zachary Roberts

Home Environmental Interventions for the Prevention or Control of Allergic and Respiratory Diseases: What Really Works

JOURNAL ARTICLE published January 2017 in The Journal of Allergy and Clinical Immunology: In Practice

Authors: Pierre Le Cann | Hélène Paulus | Philippe Glorennec | Barbara Le Bot | Sophie Frain | Jean Pierre Gangneux

Ongoing Complete Remissions in ZUMA-1: A Phase 1-2 Multicenter Study of KTE-C19 (Anti-CD19 CAR T Cells) in Patients with Refractory Aggressive B Cell Non-Hodgkin Lymphoma

JOURNAL ARTICLE published September 2016 in Clinical Lymphoma Myeloma and Leukemia

Authors: Sattva Neelapu | Frederick Locke | Nancy Bartlett | Tanya Siddiqi | Julio Chavez | Chitra Hosing | Amanda Cashen | Lihua Budde | Adrian Bot | John Rossi | Lynn Navale | Yizhou Jiang | Jeff Aycock | Meg Elias | Jeff Wiezorek | William Go

Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma.

JOURNAL ARTICLE published 20 June 2016 in Journal of Clinical Oncology

Authors: James Kochenderfer | Robert Somerville | Tangying Lu | Victoria Shi | James C. Yang | Richard Sherry | Christopher Klebanoff | Udai S. Kammula | Stephanie L. Goff | Adrian Bot | John Rossi | Marika Sherman | Arianne Perez | Allen Xue | Tatyana A. Feldman | Jonathan W. Friedberg | Mark J. Roschewski | Steven Feldman | Lori McIntyre | Steven A. Rosenberg

Prognostication using molecular (mol) markers and clinicopathological (clpath) features in high-risk stage II/III colon cancer (CC).

JOURNAL ARTICLE published 20 May 2016 in Journal of Clinical Oncology

Authors: Rodrigo Dienstmann | Sabine Tejpar | Frank A. Sinicrope | Amanda I. Phipps | Brian Bot | Stephen Henry Friend | Mauro Delorenzi | Polly A. Newcomb | Daniel J. Sargent | John M Jessup | Justin Guinney

Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma.

JOURNAL ARTICLE published 20 May 2016 in Journal of Clinical Oncology

Authors: James Kochenderfer | Robert Somerville | Tangying Lu | Victoria Shi | James C. Yang | Richard Sherry | Christopher Klebanoff | Udai S. Kammula | Stephanie L. Goff | Adrian Bot | John Rossi | Marika Sherman | Arianne Perez | Allen Xue | Tatyana A. Feldman | Jonathan W. Friedberg | Mark J. Roschewski | Steven Feldman | Lori McIntyre | Steven A. Rosenberg